TY - JOUR
T1 - Intratumor heterogeneity of HMCN1 mutant alleles associated with poor prognosis in patients with breast cancer
AU - Kikutake, Chie
AU - Yoshihara, Minako
AU - Sato, Tetsuya
AU - Saito, Daisuke
AU - Suyama, Mikita
N1 - Funding Information:
This study was supported by JSPS Grants-in-Aid for Scientific Research [Grant number: 17H03619 to M.S. and 17KT0128, 17K07257 to T.S.] and The Shin-Nihon of Advanced Medical Research [to T.S.].
Funding Information:
This work was supported by the "Advanced Computational Scientific Program" of the Research Institute for Information Technology, Kyushu University. The results shown here are partly based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This study was supported by JSPS Grants-in-Aid for Scientific Research [Grant number: 17H03619 to M.S. and 17KT0128, 17K07257 to T.S.] and The Shin-Nihon of Advanced Medical Research [to T.S.].
Funding Information:
This work was supported by the “Advanced Computational Scientific Program” of the Research Institute for Information Technology, Kyushu University. The results shown here are partly based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.
Publisher Copyright:
© Kikutake et al.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Human breast cancers comprise a complex and highly heterogeneous population of tumor cells. Intratumor heterogeneity is an underlying cause of resistance to effective therapies and disease recurrence. To explore prognostic factors based on intratumor heterogeneity, we analyzed genomic mutations in breast cancer patients registered in The Cancer Genome Atlas. We calculated the variant allele frequency (VAF) at each mutation site and evaluated the associations of VAFs with the prognosis of breast cancer. VAFs of HMCN1 correlated with the prognosis and lymph node status. Although the detailed function of HMCN1 remains unknown, it is located in extracellular matrix and the mutation in the gene might be associated with cancer cell invasion and metastasis. This finding suggests that HMCN1 is a potential metastatic factor and can be a candidate gene for targeted breast cancer therapy.
AB - Human breast cancers comprise a complex and highly heterogeneous population of tumor cells. Intratumor heterogeneity is an underlying cause of resistance to effective therapies and disease recurrence. To explore prognostic factors based on intratumor heterogeneity, we analyzed genomic mutations in breast cancer patients registered in The Cancer Genome Atlas. We calculated the variant allele frequency (VAF) at each mutation site and evaluated the associations of VAFs with the prognosis of breast cancer. VAFs of HMCN1 correlated with the prognosis and lymph node status. Although the detailed function of HMCN1 remains unknown, it is located in extracellular matrix and the mutation in the gene might be associated with cancer cell invasion and metastasis. This finding suggests that HMCN1 is a potential metastatic factor and can be a candidate gene for targeted breast cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=85053033297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053033297&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.26071
DO - 10.18632/oncotarget.26071
M3 - Article
C2 - 30279964
AN - SCOPUS:85053033297
SN - 1949-2553
VL - 9
SP - 33337
EP - 33347
JO - Oncotarget
JF - Oncotarget
IS - 70
ER -
